Navigation Links
DiObex Announces Presentation of Scientific Poster at Annual Meeting of American Society for Clinical Pharmacology and Therapeutics
Date:4/1/2008

Data supports potential use of DIO-902 with Atorvastatin

SAN FRANCISCO, April 1, 2008 /PRNewswire/ -- DiObex, Inc., a privately held biotechnology company focused on the development of therapeutics to treat metabolic diseases, announced today that a scientific poster relating to DIO-902 (levdexketoconazole) is being presented at the American Society for Clinical Pharmacology and Therapeutics annual meeting on Saturday, April 5th in Orlando. DIO-902 is being studied in Phase 2b clinical trials for the treatment of type 2 diabetes.

The poster, entitled "Differential Effects of Co-Administration of Racemic Ketoconazole and Levdexketoconazole on the Pharmacokinetic Profile of Atorvastatin," highlights the results of a study evaluating the effects of equal doses of the single enantiomer DIO-902 and racemic ketoconazole, on the pharmacokinetics of a single 80 mg dose of atorvastatin in healthy volunteers. Overall, repeated oral administration of DIO-902 tablets with atorvastatin was safe and well tolerated; in addition, DIO-902 significantly reduced cortisol levels compared with ketoconazole.

"The increase in total exposure of atorvastatin was significantly less when it was administered with DIO-902 than with racemic ketoconazole," said Dr. Tim Stewart, Vice President of Research at DiObex. "In addition, the administration of DIO-902 with atorvastatin resulted in significantly reduced cortisol levels from placebo, compared with atorvastatin administered with racemic ketoconazole. This finding supports preclinical evidence that DIO-902 is a more potent inhibitor of cortisol synthesis than ketoconazole."

DIO-902 is an oral, single enantiomer of ketoconazole, a common anti-fungal drug. DiObex is developing DIO-902 as a novel cortisol inhibitor for treating type 2 diabetes and diabetic nephropathy. There is growing evidence linking abnormal cortisol metabolism to both type 2 diabetes and metabolic syndrome, prompting a search for therapeutic agents that lower levels of cortisol or block the effects of cortisol excess. Preclinical and clinical data indicate that DIO-902 is a potent cortisol inhibitor. Clinical data also show early trends toward reductions in HbA1c, total cholesterol, LDL cholesterol, and C-reactive protein. Preclinical and clinical data also suggest that DIO-902 may be a safer and more effective agent than racemic ketoconazole.

About DiObex

DiObex, Inc. is a privately held biotechnology company developing novel products for diabetes and metabolic diseases. DiObex has two product candidates in four mid-stage clinical development programs. DIO-901 (very low dose glucagon) is in development for the prevention of insulin-induced hypoglycemia in type 1 diabetes mellitus in an extended release subcutaneous formulation and in a convenient disposable subcutaneous delivery device. DIO-901 has received Fast Track status from the FDA. DIO-902 (levdexketoconazole) is an oral, single enantiomer of ketoconazole that is a novel cortisol synthesis inhibitor in development for type 2 diabetes mellitus and diabetic nephropathy. Abnormalities in cortisol activity may play an important role in the development of metabolic syndrome, a constellation of conditions that place people at high risk for type 2 diabetes mellitus and cardiovascular disease. For more information, visit http://www.diobex.com.


'/>"/>
SOURCE DiObex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. DiObex and Camurus Sign License Agreement for the Development of DIO-901 in FluidCrystal(R) Extended Release Technology
2. DiObex, Inc. to Present at Merrill Lynch Global Healthcare Conference
3. DiObex Inc. to Present at BIO Mid-America Venture Forum
4. DaVita Announces Retirement of Former Chief Medical Officer Charles J. McAllister, M.D.
5. Human Pheromone Sciences Announces Quarterly and Full Year Results
6. Dragon Pharma announces 2007 full year financial results
7. Genaera Corporation Announces 2007 Financial Results
8. Genmab Announces Year End 2007 Financial Results
9. Immunosyn Corporation Announces 2007 Results, Files 10KSB
10. Elbit Imaging Ltd. Announces Results For Fiscal Year 2007
11. The Immune Tolerance Institute Announces Collaboration with Beckman Coulter Establishing a Multiplatform Immunophenotyping/Immunogenotyping Laboratory
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/12/2017)... ... 2017 , ... Each year, Crain’s Detroit Business News ranks the most innovative ... patent estate of a company, its impact and significance, and the likelihood of bringing ... in technologies that transform energy sources such as low dose X-ray and convert them ...
(Date:1/12/2017)... Colo (PRWEB) , ... January 12, 2017 , ... ... then to targeted treatments, 26-year-old Lisa Rosendahl’s doctors gave her only a few ... describes a new drug combination that has stabilized Rosendahl’s disease and increased both ...
(Date:1/12/2017)... PORTLAND, Oregon and Pune, India , January 12, 2017 ... In vitro Toxicity Testing Market by Type and End Users - Global Opportunity Analysis ... reach $7,813 million by 2022 from $2,921 million in 2015, growing at a CAGR ... ... Allied Market Research Logo ...
(Date:1/11/2017)... ... January 11, 2017 , ... Phase ... show early promise of the investigational anti-cancer agent tucatinib (formerly ONT-380) against HER2+ ... treatment regimens. Twenty-seven percent of these heavily pretreated patients saw clinical benefit from ...
Breaking Biology Technology:
(Date:1/3/2017)... , Jan. 3, 2017 Onitor, provider ... introduction of Onitor Track, an innovative biometric data-driven program ... showcasing this month at the 2017 Consumer Electronics Show ... In the U.S., the World Health Organization ... than two-thirds of adults who are overweight or obese. ...
(Date:12/20/2016)... N.C. and GENEVA, Dec, 20, 2016 /PRNewswire/ ... biometric data sensor technology, and STMicroelectronics ... the spectrum of electronics applications, announced today the ... development kit for biometric wearables that includes ST,s ... with Valencell,s Benchmark™ biometric sensor system. ...
(Date:12/16/2016)... -- The global wearable medical device market, in terms of value, ... 5.31 billion in 2016, at a CAGR of 18.0% during the ... ... medical devices, launch of a growing number of smartphone-based healthcare apps ... providers, and increasing focus on physical fitness. Furthermore, ...
Breaking Biology News(10 mins):